Asklepieion Hospital of Voula
Athens, Ελλάδα (+30), 16675, Greece
NCT Number: NCT06577155
60 patients ASA I-III, undergoing total hip arthroplasty were randomly assigned, into one of two groups, namely group E (n=30), where levobupivacaine will be administeral intrathecally ; and group N (n=30), where levobupivacaine plus nalbuphine will be administeral intrathecally. All patients will receive a standardized multimodal analgesic regimen, including a PENG block and PCA morphine. Morphine consumption during the first 24 hours postoperatively will be measured and additionally the investigators will record: Time of morphine first dose administration, NRS scores in static and dynamic conditions in 4 hours, 6 hours, 12 hours, 18 hours, 24 hours, 36 hours and 48 hours postoperatively, complications, patient satisfaction and duration of hospitalization.
Looking for future studies?
Notify Me18 year–80 year
All sexes
Interventional
Phase 2
Athens, Ελλάδα (+30), 16675, Greece
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Regional anesthesia / analgesia
Regional anesthesia / analgesia
Time frame: 24 hours
Time frame: 48 hours
Time frame: 1 hour
Time frame: 1 hour
Time frame: 1 hour
Time frame: 1 hour
Time frame: 4 hours
Time frame: 4 hours
Time frame: 24 hours
Asklepieion Voulas General Hospital
Other Gov
The Effect of Nalbuphine as an Adjuvant to Levobupivacaine in Subarachnoid Anesthesia in Total Hip Arthroplasty. A Double-blind, Randomized, Controlled Study.
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06573931
Agnosia, Analgesia
Tanta, El-Gharbia, Egypt
View Trial DetailsNCT07606794
Agnosia, Analgesia
Tanta, El-Gharbia, Egypt
View Trial DetailsNCT06806865
Agnosia, Nervous System Diseases
Tekirdağ, Süleymanpasa, Turkey (Türkiye)
View Trial DetailsNCT03409900
Agnosia, Arthritis
Winston-Salem, North Carolina, United States
View Trial Details